Mode
Text Size
Log in / Sign up

Olfactory decline associated with conversion to mild cognitive impairment and dementia in unimpaired adults.

Olfactory decline associated with conversion to mild cognitive impairment and dementia in unimpaired…
Photo by Growtika / Unsplash
Key Takeaway
Recognize olfactory decline associates with MCI conversion risk in this retrospective cohort without establishing causality.

This retrospective longitudinal analysis utilized data from the Arizona Study of Aging and Neurodegenerative Disorders involving 922 cognitively unimpaired individuals without parkinsonism. The study tracked participants over a mean follow-up of 7.7 (5.4) years to assess olfactory decline as an exposure.

Olfactory function was significantly reduced in converters compared to non-converters with a t-value of -12.6 and p <0.0001. Converters also demonstrated faster progression in neuropsychiatric symptom burden (t=3.42, p < 0.001) and faster memory decline (t= -7.33, p<0.0001). Motor scores showed no significant differences between groups.

Prediction accuracy for conversion to MCI reached ~ 70% when combining olfactory decline, neuropsychiatric burden, motor, and memory decline. Using the UPSIT alone yielded ~ 60% accuracy. Higher alpha-synuclein burden (t= -8.21, p<0.0005), Tau tangle burden (t= -2.66, p < 0.01), and Amyloid plaque burden (t= -2.85, p <0.005) were associated with longitudinal decline in olfaction. Tau burden (t=5.66, p<0.0001) associated with faster decline.

Safety data were not reported. The study design is retrospective, indicating association rather than causation. Incorporating olfactory testing in cognitively unimpaired individuals may help identify those at risk of future cognitive decline.

Study Details

Study typeCohort
Sample sizen = 922
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Importance: Decline in olfactory function may be used as a predictor of cognitive decline, to enhance early detection models, improve risk stratification, and enable early intervention. Objective: To assess the longitudinal association between olfactory decline, cognitive decline, and postmortem neuropathology. Design, setting and participants: Retrospective longitudinal analysis with clinicopathological correlations of a prospective population-based cohort study using data from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) and its Brain and Body Donation Program. Participants included cognitively unimpaired individuals without parkinsonism that converted to mild cognitive impairment (MCI) and/or dementia or remained cognitively stable. Main Outcomes and Measures: longitudinal change in olfaction, neuropsychiatric symptoms, motor function and memory, conversion to MCI/dementia, postmortem neuropathology Results: Over a mean follow-up period of 7.7 (5.4) years, out of 922 participants who were cognitively unimpaired at the first cognitive conference, 643 remained cognitively unimpaired, 279 converted to MCI, and 82 developed dementia. Of these, 633 individuals had at least 2 olfactory tests. Converters showed reduced olfactory function (t=-12.6, p <0.0001), faster progression in neuropsychiatric symptom burden (t=3.42, p < 0.001), and faster decline in memory (t= -7.33, p <0.0001) prior to conversion while no significant differences were observed in motor scores between converters and non-converters. Using ROC analysis, olfactory decline, increased neuropsychiatric symptom burden, as well as motor and memory decline predicted conversion to MCI with a consistent accuracy of ~ 70% up to 5 years before conversion, while UPSIT alone had an accuracy of ~ 60%. Longitudinal decline in olfaction was associated with a higher burden of a-synuclein (t= -8.21, p <0.0005), tau tangle (t= -2.66, p < 0.01) and amyloid plaque burden (t= -2.85, p < 0.005) and a faster decline over time was associated with a higher burden of tau (t=5.66, p<0.0001). Conclusions and Relevance: A reduction in olfactory identification ability is observed up to a decade prior to conversion to MCI and is associated with underlying burden of neuropathology markers, underscoring the value of incorporating olfactory testing in cognitively unimpaired individuals to identify those at-risk of future cognitive decline.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.